Trials / Completed
CompletedNCT05632393
A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women
A Prospective, Open-label, Single-dose Phase 1 Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Idorsia Pharmaceuticals Ltd. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
A study to measure daridorexant in breast milk of healthy lactating women
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Daridorexant | Daridorexant will be available as film-coated tablets for oral administration formulated at a strength of 50 mg. |
Timeline
- Start date
- 2023-01-16
- Primary completion
- 2023-04-30
- Completion
- 2023-04-30
- First posted
- 2022-11-30
- Last updated
- 2023-05-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05632393. Inclusion in this directory is not an endorsement.